Tags

Type your tag names separated by a space and hit enter

Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.
Cancer Epidemiol 2019; 62:101585CE

Abstract

BACKGROUND

There is increasing interest in the potential association between proton pump inhibitors (PPIs) and the risk of gastric and oesophageal cancer, yet the effect of duration of treatment needs clarification.

METHODS

This Swedish population-based cohort study assessed the influence of time since initiation of PPI treatment on the risk of gastric and oesophageal cancer, presented as standardised incidence ratios and 95% confidence intervals.

RESULTS

The risk of gastric and oesophageal cancer during the first year was 7-10 times higher than the background population, and remained 24-202% increased without any decrease over time after the first year.

CONCLUSION

PPI use was associated with an increased risk of gastric and oesophageal cancer and the risk remained increased over follow-up. These results support our original hypothesis that use of PPIs may be a risk factor for gastric and oesophageal cancer in the general population of maintenance users, independent of underlying indications.

Authors+Show Affiliations

Centre for Translational Microbiome Research, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden; Science for Life Laboratory (SciLifeLab), Stockholm, Sweden; Department of Head and Skin, Faculty of Medicine, Ghent University, Ghent, Belgium. Electronic address: Nele.Brusselaers@ki.se.Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom.Centre for Translational Microbiome Research, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden; Science for Life Laboratory (SciLifeLab), Stockholm, Sweden.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31445426

Citation

Brusselaers, Nele, et al. "Duration of Use of Proton Pump Inhibitors and the Risk of Gastric and Oesophageal Cancer." Cancer Epidemiology, vol. 62, 2019, p. 101585.
Brusselaers N, Lagergren J, Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol. 2019;62:101585.
Brusselaers, N., Lagergren, J., & Engstrand, L. (2019). Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiology, 62, p. 101585. doi:10.1016/j.canep.2019.101585.
Brusselaers N, Lagergren J, Engstrand L. Duration of Use of Proton Pump Inhibitors and the Risk of Gastric and Oesophageal Cancer. Cancer Epidemiol. 2019 Aug 21;62:101585. PubMed PMID: 31445426.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. AU - Brusselaers,Nele, AU - Lagergren,Jesper, AU - Engstrand,Lars, Y1 - 2019/08/21/ PY - 2019/06/25/received PY - 2019/08/13/revised PY - 2019/08/14/accepted PY - 2019/8/25/pubmed PY - 2019/8/25/medline PY - 2019/8/25/entrez KW - Adenocarcinoma KW - Carcinoma KW - Esophageal neoplasms KW - Neoplasms KW - Proton pump inhibitors KW - Squamous cell KW - Stomach neoplasms SP - 101585 EP - 101585 JF - Cancer epidemiology JO - Cancer Epidemiol VL - 62 N2 - BACKGROUND: There is increasing interest in the potential association between proton pump inhibitors (PPIs) and the risk of gastric and oesophageal cancer, yet the effect of duration of treatment needs clarification. METHODS: This Swedish population-based cohort study assessed the influence of time since initiation of PPI treatment on the risk of gastric and oesophageal cancer, presented as standardised incidence ratios and 95% confidence intervals. RESULTS: The risk of gastric and oesophageal cancer during the first year was 7-10 times higher than the background population, and remained 24-202% increased without any decrease over time after the first year. CONCLUSION: PPI use was associated with an increased risk of gastric and oesophageal cancer and the risk remained increased over follow-up. These results support our original hypothesis that use of PPIs may be a risk factor for gastric and oesophageal cancer in the general population of maintenance users, independent of underlying indications. SN - 1877-783X UR - https://www.unboundmedicine.com/medline/citation/31445426/Duration_of_use_of_proton_pump_inhibitors_and_the_risk_of_gastric_and_oesophageal_cancer L2 - https://linkinghub.elsevier.com/retrieve/pii/S1877-7821(19)30096-7 DB - PRIME DP - Unbound Medicine ER -